By now, the adverse effects of the asthma medication Xolair® have been well-reported by sources including WebMD, Lung Disease News and the Food and Drug Administration. Most serious among these complications are chest pain, heart attacks, “mini-strokes,” blood clots, brain issues and a severe, life-threatening allergic reaction known as anaphylaxis. There is even some evidence that it may increase the risk of cancer - which may have to do with its mechanism of action, or how the medication works in the body.
Earlier this year, the U.S. Food and Drug Administration, medical authorities in the E.U. and Health Canada approved the controversial asthma drug, Xolair, for the treatment of hives, or urticara, a painful skin condition marked by pink, itchy rashes. This drug has been implicated in an increased risk of suffocation from anaphylaxis (a blockage of the air passage caused by throat swelling among other side effects). Drug makers Genentech and Novartis are finding that approval for this purpose in Great Britain is not quite as easy, however.